Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Parkinson's Disease

  Free Subscription


Articles published in Ann Neurol

Retrieve available abstracts of 49 articles:
HTML format
Text format



Single Articles


    December 2016
  1. PAGANO G, Niccolini F, Fusar-Poli P, Politis M, et al
    Serotonin transporter in Parkinson's disease: A meta-analysis of PET studies.
    Ann Neurol. 2016 Dec 26. doi: 10.1002/ana.24859.
    PubMed     Text format     Abstract available


  2. BRAKEDAL B, Haugarvoll K, Tzoulis C
    Simvastatin is associated with decreased risk of Parkinson Disease.
    Ann Neurol. 2016 Dec 26. doi: 10.1002/ana.24857.
    PubMed     Text format    


  3. YEN SJ, Lin KD
    Reply to "Simvastatin is associated with decreased risk of Parkinson Disease" by Brage Brakedal.
    Ann Neurol. 2016 Dec 26. doi: 10.1002/ana.24862.
    PubMed     Text format    


    October 2016
  4. LIN KD, Shin SJ
    Reply to 'Risk reduction of Parkinson disease by statin therapy in patients with diabetes' by T. Kawada.
    Ann Neurol. 2016 Oct 31. doi: 10.1002/ana.24813.
    PubMed     Text format    


  5. KAWADA T
    Risk reduction of Parkinson disease by statin therapy in patients with diabetes.
    Ann Neurol. 2016 Oct 27. doi: 10.1002/ana.24809.
    PubMed     Text format    


  6. STANDAERT DG, Geldmacher DS
    GBA, Parkinson disease, and the "senses and intellect".
    Ann Neurol. 2016 Oct 25. doi: 10.1002/ana.24808.
    PubMed     Text format    


  7. INZELBERG R, Flash S, Friedman E, Azizi E, et al
    Cutaneous malignant melanoma and Parkinson's disease: common pathways?
    Ann Neurol. 2016 Oct 19. doi: 10.1002/ana.24802.
    PubMed     Text format     Abstract available


    September 2016
  8. LIU G, Boot B, Locascio JJ, Jansen IE, et al
    Neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's.
    Ann Neurol. 2016 Sep 22. doi: 10.1002/ana.24781.
    PubMed     Text format     Abstract available


  9. CILIA R, Tunesi S, Marotta G, Cereda E, et al
    Survival and dementia in GBA-associated Parkinson Disease: The mutation matters.
    Ann Neurol. 2016 Sep 15. doi: 10.1002/ana.24777.
    PubMed     Text format     Abstract available


    July 2016
  10. LIN KD, Yang CY, Lee MY, Ho SC, et al
    Statin Therapy Prevents the Onset of Parkinson Disease in Patients with Diabetes.
    Ann Neurol. 2016 Jul 29. doi: 10.1002/ana.24751.
    PubMed     Text format     Abstract available


    June 2016
  11. MITROFANIS J, Moro C, Benabid AL
    Further analysis of the neuroprotective effect of near-infrared light in a monkey model of Parkinson disease.
    Ann Neurol. 2016 Jun 4. doi: 10.1002/ana.24696.
    PubMed     Text format    


    April 2016
  12. GUELLA I, Evans DM, Szu-Tu C, Nosova E, et al
    alpha-synuclein genetic variability: A biomarker for dementia in Parkinson's disease.
    Ann Neurol. 2016 Apr 18. doi: 10.1002/ana.24664.
    PubMed     Text format     Abstract available


  13. JIANG T, Zhang YD, Tan L, Yu JT, et al
    DNAJC6 variants in Parkinson's disease and amyotrophic lateral sclerosis.
    Ann Neurol. 2016 Apr 4. doi: 10.1002/ana.24658.
    PubMed     Text format    


    March 2016
  14. STOKHOLM MG, Danielsen EH, Hamilton-Dutoit SJ, Borghammer P, et al
    Pathological alpha-synuclein in gastrointestinal tissues from prodromal parkinson's disease patients.
    Ann Neurol. 2016 Mar 26. doi: 10.1002/ana.24648.
    PubMed     Text format     Abstract available


  15. TELL-MARTI G, Anton Puig-Butille J, Potrony M, Badenas C, et al
    Reply to Letter to Editor ANA-16-0021 'Lack of association between MC1R variants and Parkinson's disease in European descent' by Jiang Q and Liu G.
    Ann Neurol. 2016 Mar 2. doi: 10.1002/ana.24629.
    PubMed     Text format    


  16. JIANG Q, Liu G
    Lack of association between MC1R variants and Parkinson's disease in European descent.
    Ann Neurol. 2016 Mar 2. doi: 10.1002/ana.24627.
    PubMed     Text format    


    December 2015
  17. ELSAYED LE, Drouet V, Usenko T, Mohammed IN, et al
    A novel nonsense mutation in DNAJC6 expands the phenotype of autosomal recessive juvenile-onset Parkinson disease.
    Ann Neurol. 2015 Dec 24. doi: 10.1002/ana.24591.
    PubMed     Text format    


  18. POSTON KL, YorkWilliams S, Zhang K, Cai W, et al
    Compensatory Neural Mechanisms in Cognitively Unimpaired Parkinson's Disease.
    Ann Neurol. 2015 Dec 22. doi: 10.1002/ana.24585.
    PubMed     Text format     Abstract available


  19. LORENZO-BETANCOR O, Wszolek ZK, Ross OA
    Rare variants in MC1R/TUBB3 exon 1 are not associated with Parkinson's disease.
    Ann Neurol. 2015 Dec 17. doi: 10.1002/ana.24581.
    PubMed     Text format    


    November 2015
  20. DONADIO V, Incensi A, Piccinini C, Cortelli P, et al
    Skin nerve misfolded alpha-synuclein in pure autonomic failure and Parkinson disease.
    Ann Neurol. 2015 Nov 25. doi: 10.1002/ana.24567.
    PubMed     Text format     Abstract available


  21. GRUNEWALD A, Rygiel KA, Hepplewhite PD, Morris CM, et al
    Mitochondrial DNA depletion in respiratory chain-deficient Parkinson disease neurons.
    Ann Neurol. 2015 Nov 25. doi: 10.1002/ana.24571.
    PubMed     Text format     Abstract available


  22. OLGIATI S, Quadri M, Fang M, Rood JP, et al
    DNAJC6 mutations associated with early-onset Parkinson's disease.
    Ann Neurol. 2015 Nov 3. doi: 10.1002/ana.24553.
    PubMed     Text format     Abstract available


    October 2015
  23. DARLOT F, Moro C, El Massri N, Chabrol C, et al
    Near-infrared light is neuroprotective in a monkey model of Parkinson's disease.
    Ann Neurol. 2015 Oct 11. doi: 10.1002/ana.24542.
    PubMed     Text format     Abstract available


  24. KAUFMANN H
    Cutting the vagal highway blocks one point of entry for prion-like alpha-synuclein.
    Ann Neurol. 2015;78:520-1.
    PubMed     Text format    


    September 2015
  25. TYSNES OB, Kenborg L, Herlofson K, Steding-Jessen M, et al
    Does vagotomy reduce the risk of Parkinson's disease?
    Ann Neurol. 2015 Sep 29. doi: 10.1002/ana.24531.
    PubMed     Text format    


  26. LUBBE SJ, Escott-Price V, Brice A, Gasser T, et al
    Is the MC1R variant p.R160W associated with Parkinson's?
    Ann Neurol. 2015 Sep 21. doi: 10.1002/ana.24527.
    PubMed     Text format    


  27. TELL-MARTI G, Puig-Butille JA, Potrony M, Badenas C, et al
    Reply to Letter to Editor ANA-15-1051 'Is the MC1R variant p.R160W associated with Parkinson's?' by Lubbe SJ, Escott-Price V, Brice A, et al.
    Ann Neurol. 2015 Sep 21. doi: 10.1002/ana.24526.
    PubMed     Text format    


  28. SVENSSON E, Horvath-Puho E, Thomsen RW, Djurhuus JC, et al
    Does vagotomy reduce the risk of Parkinson's disease - the authors reply.
    Ann Neurol. 2015 Sep 15. doi: 10.1002/ana.24518.
    PubMed     Text format    


  29. PYLE A, Brennan R, Kurzawa-Akanbi M, Yarnall A, et al
    Reduced CSF mitochondrial DNA is a biomarker for early-stage Parkinson's disease.
    Ann Neurol. 2015 Sep 7. doi: 10.1002/ana.24515.
    PubMed     Text format     Abstract available


    August 2015
  30. SWANN NC, de Hemptinne C, Aron AR, Ostrem JL, et al
    Elevated synchrony in Parkinson's disease detected with electroencephalography.
    Ann Neurol. 2015 Aug 20. doi: 10.1002/ana.24507.
    PubMed     Text format     Abstract available


  31. NAZERI A, Roostaei T, Sadaghiani S, Chakravarty MM, et al
    Genome-wide variant by serum urate interaction in Parkinson's Disease.
    Ann Neurol. 2015 Aug 18. doi: 10.1002/ana.24504.
    PubMed     Text format     Abstract available


  32. GRAY MT, Munoz DG, Schlossmacher MG, Gray DA, et al
    Protective effect of vagotomy suggests source organ for Parkinson's disease.
    Ann Neurol. 2015 Aug 12. doi: 10.1002/ana.24501.
    PubMed     Text format    


  33. SVENSSON E, Horvath-Puho E, Thomsen RW, Djurhuus JC, et al
    Re: Protective effect of vagotomy suggests source organ for Parkinson's disease.
    Ann Neurol. 2015 Aug 12. doi: 10.1002/ana.24500.
    PubMed     Text format    


    July 2015
  34. TELL-MARTI G, Puig-Butille JA, Potrony M, Badenas C, et al
    Reply: To PMID 25631192.
    Ann Neurol. 2015;78:153-4.
    PubMed     Text format    


  35. VANDERHORST VG, Samardzic T, Saper CB, Anderson MP, et al
    alpha-Synuclein pathology accumulates in sacral spinal visceral sensory pathways.
    Ann Neurol. 2015;78:142-9.
    PubMed     Text format     Abstract available


    June 2015
  36. WARREN OLANOW C, Bartus RT, Baumann TL, Factor S, et al
    Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial.
    Ann Neurol. 2015 Jun 10. doi: 10.1002/ana.24436.
    PubMed     Text format     Abstract available


    May 2015
  37. SVENSSON E, Horvath-Puho E, Thomsen RW, Djurhuus JC, et al
    Vagotomy and subsequent risk of Parkinson's disease.
    Ann Neurol. 2015 May 29. doi: 10.1002/ana.24448.
    PubMed     Text format     Abstract available


    April 2015
  38. FOO JN, Zhao Y, Liu J, Tan EK, et al
    Nonsynonymous variants in MC1R are rare in Chinese Parkinson's disease cases.
    Ann Neurol. 2015 Apr 20. doi: 10.1002/ana.24419.
    PubMed     Text format    


    March 2015
  39. POTTS LF, Park ES, Woo JM, Dyavar Shetty BL, et al
    Dual kappa-agonist/mu-antagonist opioid receptor modulation reduces levodopa-induced dyskinesia and corrects dysregulated striatal changes in the nonhuman primate model of Parkinson disease.
    Ann Neurol. 2015 Mar 27. doi: 10.1002/ana.24375.
    PubMed     Text format     Abstract available


  40. CARELLI V, Musumeci O, Caporali L, Zanna C, et al
    Syndromic parkinsonism and dementia associated with OPA1 missense mutations.
    Ann Neurol. 2015 Mar 26. doi: 10.1002/ana.24410.
    PubMed     Text format     Abstract available


  41. ESCOTT-PRICE V, Nalls MA, Morris HR, Lubbe S, et al
    Polygenic risk of Parkinson disease is correlated with disease age at onset.
    Ann Neurol. 2015 Mar 13. doi: 10.1002/ana.24335.
    PubMed     Text format     Abstract available


  42. STEELE JC, Guella I, Szu-Tu C, Lin MK, et al
    Defining neurodegeneration on Guam by targeted genomic sequencing.
    Ann Neurol. 2015;77:458-68.
    PubMed     Text format     Abstract available


    February 2015
  43. GARDNER RC, Burke JF, Nettiksimmons J, Goldman S, et al
    Traumatic brain injury in later life increases risk for Parkinson's disease.
    Ann Neurol. 2015 Feb 27. doi: 10.1002/ana.24396.
    PubMed     Text format     Abstract available


  44. ALONSO A, Huang X, Mosley TH, Heiss G, et al
    Heart rate variability and the risk of Parkinson's disease: The Atherosclerosis Risk in Communities (ARIC) Study.
    Ann Neurol. 2015 Feb 23. doi: 10.1002/ana.24393.
    PubMed     Text format     Abstract available


  45. CHRISTOPHER L, Duff-Canning S, Koshimori Y, Segura B, et al
    Salience network and parahippocampal dopamine dysfunction in memory-impaired Parkinson disease.
    Ann Neurol. 2015;77:269-80.
    PubMed     Text format     Abstract available


    January 2015
  46. TELL-MARTI G, Puig-Butille JA, Potrony M, Badenas C, et al
    The MC1R melanoma risk variant p.R160W is associated with Parkinson's disease.
    Ann Neurol. 2015 Jan 29. doi: 10.1002/ana.24373.
    PubMed     Text format     Abstract available


  47. KATZ M, San Luciano M, Carlson K, Luo P, et al
    The differential effects of DBS target on motor subtypes in Parkinson's disease.
    Ann Neurol. 2015 Jan 27. doi: 10.1002/ana.24374.
    PubMed     Text format     Abstract available


  48. ESCHBACH J, von Einem B, Muller K, Bayer H, et al
    Mutual exacerbation of peroxisome proliferator-activated receptor gamma coactivator 1alpha deregulation and alpha-synuclein oligomerization.
    Ann Neurol. 2015;77:15-32.
    PubMed     Text format     Abstract available


    November 2014
  49. PERLMUTTER JS, Norris SA
    Neuroimaging biomarkers for Parkinson disease: Facts and fantasy.
    Ann Neurol. 2014 Nov 1. doi: 10.1002/ana.24291.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Parkinson's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: